MEDSIR’s Post

Researchers have developed a personalized treatment for advanced prostate cancer that the FDA has fast-tracked after a promising clinical trial. The new therapy, SYNC-T SV-102 by Syncromune Inc., showed that nearly 40% of participants had complete cancer remission. This treatment targets metastatic castration-resistant prostate cancer (mCRPC), stimulating the immune system to attack the cancer. In trials, 85% of participants responded positively, a significant improvement over standard treatments. Broader clinical trials are set to begin later this year. Read more: https://lnkd.in/dpK6gpyv #medical #healthcare #oncology #cancerresearch #immunesystem

Big ups to Russell C. Langan, MD, FACS, FSSO and RWJBarnabas Health for winning the 14th annual ACCC Innovator Awards which recognize visionary and compelling ideas in oncology from the ACCC! “In the 2 years following program implementation, 82 pancreatic cancers were detected from incidental findings with 65% of patients being diagnosed in earlier stages (stages I, II, and III), as well as instances of ampullary cancer, gallbladder cancer, and gastric cancer.” #defydisease https://lnkd.in/geeHnxAQ

According to the recently released 2024 Cancer Facts & Figures report from the American Cancer Society, more than 2 million new cancer cases will be diagnosed in the U.S. this year. This is the first year ever that new cancer cases are expected to exceed 2 million. Nearly 38,000 of those cancer cases will be diagnosed in Minnesota. This trend is likely caused by the aging and growth of the U.S. population and by a rise in diagnoses of 6 of the 10 most common cancers: breast, prostate, endometrial, pancreatic, kidney, and melanoma. Learn more: https://lnkd.in/em6XYMCv #MNCCTN #cancer #clinicaltrials #cancerresearch #oncology #health #healthcare

ASCO 2024 Cutting-edge research unveils a Triple targeting therapy for hormone receptor-positive (HR+) breast cancer, integrating Pi3Ki, CDK4/6i, and ET with remarkable tolerability. Additional analyses from the INAVO120 Phase III trial illuminate promising outcomes for patients with PIK3CA-mutated breast cancer, a challenging subgroup. This innovative approach not only demonstrates efficacy but also prioritizes patient well-being by minimizing side effects. These findings signify a significant step forward in personalized treatment strategies, offering hope for improved outcomes and enhanced quality of life for breast cancer patients. To know more read: https://lnkd.in/d7Aep_3q #BreastCancer #ASCO2024 #ResearchInnovation

FAQ Integrative Oncology Virtual Series  Why is this series available “for every ND”? How will it help a pracitioner in private practice? Who is the target audience for this webinar series? NDs and integrative practitioners with a general practice strive to support patients holistically, considering the whole person rather than just the diagnosis. This series emphasizes guiding and supporting patients with a cancer diagnosis in their overall health and well-being, rather than directly treating cancer. Recognizing that cancer patients have unique needs requiring specific knowledge from their providers, this series aims to equip you with the essential insights needed to be ‘oncology-informed.’ Our panel of experts will address the most common questions encountered in primary care, empowering you with the tools and understanding to better support your patients on their journey. More FAQ and link to register [ https://lnkd.in/e5ansQuK] . . . #webinar #freewebinar #webinarseries #oncology #cancer #canadians

#ClinicalTrialSpotlight: Ulixertinib – our highly selective, first-in-class ERK 1/2 inhibitor – is being studied in combination with the CDK4/6 inhibitor palbociclib in patients with RAS-mutated melanoma at the UNC Lineberger Comprehensive Cancer Center. This is an expansion cohort of the completed Phase 1 study evaluating this combination therapy in patients with advanced solid tumors and previously treated metastatic pancreatic cancers (NCT03454035), which established the safety profile and recommended Phase 2 dose of ulixertinib when combined with palbociclib in these patient populations. Learn more: https://lnkd.in/eRFdwnyG #CancerResearch #ClinicalTrials #DrugDevelopment 

Non-Small Cell Lung Cancer (NSCLC) continues to be a primary focus area, with leading companies channeling significant resources into its research. Despite a broader decrease in trial initiations, NSCLC remains crucial for cancer research, reflecting ongoing efforts to enhance therapeutic strategies and patient outcomes in oncology. Dive into Citeline's report for an in-depth review of how disease focus areas are evolving in the clinical trial landscape: https://lnkd.in/gGzP7yTK #Oncology #ClinicalTrials #CancerResearch #NSCLC

📣 In this first-of-its-kind study, we showed that #Immunotherapy could be used to prevent #Cancer. 🔊 We showed that Immunotherapy decreases secondary cancer by almost 70% (P<0.01). ⚡Our study has paved the way for a revolutionary approach: Preventative Immunotherapy, a promising new avenue in the battle against cancer. 🔔 Check out our abstract in the coming #ASCO24. Cleveland Clinic Merck Bristol Myers Squibb AstraZeneca Roche Jame Abraham, M.D. FACP American Society of Clinical Oncology (ASCO) #ASCO #Oncology #ClevelandClinic

On World Lung Cancer Day, we join the global community in raising awareness about a disease we know all too well. Advancing and accelerating oncology research is core to who we are. See Precision experts in action in an international Phase 1 trial for NSCLC: https://hubs.ly/Q02JJG1h0 #oncology #clinicaltrials #clinicalresearch

As the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concludes, we reflect on the innovative discoveries unveiled this year. In a new article, Henar Hevia, Senior Director and EMEA Therapeutic Area Lead for Oncology, goes one step further, delving into the past, present as well as the future of lung cancer care, since the ground-breaking identification of EGFR mutations in lung cancer, and how this has paved the way for improved patient outcomes. Read it here: https://lnkd.in/eH5tTg5G #ASCO24 #PrecisionMedicine #LungCancer #InFrontOfCancer